BG104432A - Терапевтично използване на хинолинови производни - Google Patents
Терапевтично използване на хинолинови производни Download PDFInfo
- Publication number
- BG104432A BG104432A BG104432A BG10443200A BG104432A BG 104432 A BG104432 A BG 104432A BG 104432 A BG104432 A BG 104432A BG 10443200 A BG10443200 A BG 10443200A BG 104432 A BG104432 A BG 104432A
- Authority
- BG
- Bulgaria
- Prior art keywords
- quinolinylmethyloxy
- compound
- alkyl
- tetrazole
- phenoxymethyl
- Prior art date
Links
- 0 *CNC(Cc1cccc(COC(C2)C=CC=C2OCC2N=C(C=CC=C3)C3=CC2)c1)=N Chemical compound *CNC(Cc1cccc(COC(C2)C=CC=C2OCC2N=C(C=CC=C3)C3=CC2)c1)=N 0.000 description 3
- AWHSQBQAQBXRMH-UHFFFAOYSA-N C(c(cc1)ccc1-c1nnn[nH]1)Oc1cccc(OCc2nc3ccccc3cc2)c1 Chemical compound C(c(cc1)ccc1-c1nnn[nH]1)Oc1cccc(OCc2nc3ccccc3cc2)c1 AWHSQBQAQBXRMH-UHFFFAOYSA-N 0.000 description 1
- KSLJQZMWPJNKKP-UHFFFAOYSA-O C(c(cc1)ccc1OCc1nc2ccccc2cc1)Oc(cc1)ccc1-c1n[nH+]n[nH]1 Chemical compound C(c(cc1)ccc1OCc1nc2ccccc2cc1)Oc(cc1)ccc1-c1n[nH+]n[nH]1 KSLJQZMWPJNKKP-UHFFFAOYSA-O 0.000 description 1
- KOXHPVHOZNZZSJ-UHFFFAOYSA-N C(c1cc(OCc2nc3ccccc3cc2)ccc1)Oc1cccc(-c2nnn[nH]2)c1 Chemical compound C(c1cc(OCc2nc3ccccc3cc2)ccc1)Oc1cccc(-c2nnn[nH]2)c1 KOXHPVHOZNZZSJ-UHFFFAOYSA-N 0.000 description 1
- WLGCQGMQMAOULL-UHFFFAOYSA-N C(c1cccc(-c2nnn[nH]2)c1)Oc1cc(OCc2nc3ccccc3cc2)ccc1 Chemical compound C(c1cccc(-c2nnn[nH]2)c1)Oc1cc(OCc2nc3ccccc3cc2)ccc1 WLGCQGMQMAOULL-UHFFFAOYSA-N 0.000 description 1
- LRHAGGWPAYKDOL-UHFFFAOYSA-N C(c1nnn[nH]1)Oc1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)cc1 Chemical compound C(c1nnn[nH]1)Oc1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)cc1 LRHAGGWPAYKDOL-UHFFFAOYSA-N 0.000 description 1
- SSPUCOWJOYUIGO-UHFFFAOYSA-N COC(c1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)c(OCc2nnn[nH]2)c1)=O Chemical compound COC(c1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)c(OCc2nnn[nH]2)c1)=O SSPUCOWJOYUIGO-UHFFFAOYSA-N 0.000 description 1
- PTSDFSPWBZHXMQ-UHFFFAOYSA-N OC(COc(c(COc1cc(OCc2nc3ccccc3cc2)ccc1)ccc1)c1Cl)=O Chemical compound OC(COc(c(COc1cc(OCc2nc3ccccc3cc2)ccc1)ccc1)c1Cl)=O PTSDFSPWBZHXMQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6231897P | 1997-10-17 | 1997-10-17 | |
US6590297P | 1997-11-17 | 1997-11-17 | |
PCT/US1998/021947 WO1999020275A1 (fr) | 1997-10-17 | 1998-10-16 | Utilisations therapeutiques de derives de quinoline |
Publications (1)
Publication Number | Publication Date |
---|---|
BG104432A true BG104432A (bg) | 2000-12-29 |
Family
ID=26742119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG104432A BG104432A (bg) | 1997-10-17 | 2000-05-15 | Терапевтично използване на хинолинови производни |
Country Status (17)
Country | Link |
---|---|
US (1) | US6376512B1 (fr) |
EP (1) | EP1030665A4 (fr) |
JP (1) | JP2001520193A (fr) |
KR (1) | KR20010024533A (fr) |
CN (1) | CN1302206A (fr) |
AP (1) | AP2000001786A0 (fr) |
AU (1) | AU9696198A (fr) |
BG (1) | BG104432A (fr) |
BR (1) | BR9814087A (fr) |
CA (1) | CA2306825A1 (fr) |
EA (1) | EA200000427A1 (fr) |
HU (1) | HUP0101022A1 (fr) |
IL (1) | IL135673A0 (fr) |
NO (2) | NO20001962L (fr) |
OA (1) | OA11371A (fr) |
PL (1) | PL344977A1 (fr) |
WO (1) | WO1999020275A1 (fr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
ES2261202T3 (es) * | 1999-04-28 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de acido de triarilo como ligandos para el receptor ppar. |
US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
CA2382966A1 (fr) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Derives de biaryl-oxa(thia)zole et leur utilisation en tant que modulateurs de ppar |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
JP2001261654A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6653332B2 (en) * | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
US20030171399A1 (en) * | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
EP1357115B1 (fr) | 2000-12-28 | 2009-06-17 | Takeda Pharmaceutical Company Limited | Derives d'acide alcanoique, procede de production et utilisation correspondants |
EP1911462A3 (fr) | 2001-01-26 | 2011-11-30 | Schering Corporation | Combinaisons comprenant un inhibiteur d'absorption de stérol |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
NZ530051A (en) | 2001-06-12 | 2006-12-22 | Wellstat Therapeutics Corp | Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders |
EP1452521A4 (fr) * | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | Compose cyclique et agoniste du recepteur ppar |
SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
DK1517883T3 (da) | 2002-06-20 | 2008-05-26 | Astrazeneca Ab | Ortho-substituerede benzoesyrederivater til behandling af insulinresistens |
JP4579681B2 (ja) | 2002-07-09 | 2010-11-10 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法 |
JP4531049B2 (ja) * | 2003-09-17 | 2010-08-25 | ノバルティス アーゲー | 有機化合物 |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
WO2005105736A1 (fr) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
RU2008108221A (ru) * | 2005-09-07 | 2009-10-20 | Плекссикон, Инк. (Us) | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) |
EP1979311B1 (fr) | 2005-12-22 | 2012-06-13 | High Point Pharmaceuticals, LLC | Acides phénoxyacétiques en tant qu'activateurs ppar delta |
CA2645719A1 (fr) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Nouveaux composes, leur preparation et utilisation |
CA2663121C (fr) | 2006-09-08 | 2016-01-19 | Rhode Island Hospital | Traitement, prevention et elimination d'une maladie cerebrale d'origine alcoolique |
US7645616B2 (en) | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
ES2561039T3 (es) | 2008-04-30 | 2016-02-24 | Wellstat Therapeutics Corporation | Compuestos tetrazol para reducir el ácido úrico |
JP2012529517A (ja) | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ベンジル置換トリアジン誘導体類及びそれらの治療応用 |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
WO2010144586A1 (fr) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Dérivés de l'isoquinoléine, de la quinoléine et de la quinazoléine servant d'inhibiteurs de signal hedgehog |
EP2590951B1 (fr) | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques |
JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体 |
CA2804351A1 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Composes chimiques |
JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体 |
JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
WO2015157187A1 (fr) * | 2014-04-06 | 2015-10-15 | Sanford-Burnham Medical Research Institute | Modulateurs allostériques positifs (pam) du récepteur métabotropique du glutamate et leurs utilisations |
CN116323560A (zh) * | 2020-08-04 | 2023-06-23 | 精密生物治疗有限责任公司 | 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US4920130A (en) * | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
PT731791E (pt) * | 1993-11-29 | 2000-11-30 | Merrell Pharma Inc | Novos derivados de benzeno-sulfonil-imina como inibidores da accao da il-1. |
EP0709377B1 (fr) * | 1994-10-27 | 1999-09-29 | Asahi Glass Company Ltd. | Procédé pour la préparation de composés d'acide benzoique |
EP0871439B1 (fr) * | 1996-01-02 | 2004-03-31 | Aventis Pharmaceuticals Inc. | Composes d'acide (aryle, heteroaryle, arylmethyle ou heteroarylmethyle) hydroxamique substitues |
-
1998
- 1998-10-16 PL PL98344977A patent/PL344977A1/xx unknown
- 1998-10-16 IL IL13567398A patent/IL135673A0/xx unknown
- 1998-10-16 JP JP2000516672A patent/JP2001520193A/ja active Pending
- 1998-10-16 EA EA200000427A patent/EA200000427A1/ru unknown
- 1998-10-16 CA CA002306825A patent/CA2306825A1/fr not_active Abandoned
- 1998-10-16 WO PCT/US1998/021947 patent/WO1999020275A1/fr not_active Application Discontinuation
- 1998-10-16 KR KR1020007004131A patent/KR20010024533A/ko not_active Application Discontinuation
- 1998-10-16 CN CN98811303A patent/CN1302206A/zh active Pending
- 1998-10-16 HU HU0101022A patent/HUP0101022A1/hu unknown
- 1998-10-16 EP EP98951075A patent/EP1030665A4/fr not_active Withdrawn
- 1998-10-16 AU AU96961/98A patent/AU9696198A/en not_active Abandoned
- 1998-10-16 BR BR9814087-6A patent/BR9814087A/pt not_active Application Discontinuation
-
2000
- 2000-01-27 US US09/490,897 patent/US6376512B1/en not_active Expired - Fee Related
- 2000-04-07 AP APAP/P/2000/001786A patent/AP2000001786A0/en unknown
- 2000-04-13 OA OA1200000106A patent/OA11371A/en unknown
- 2000-04-14 NO NO20001962A patent/NO20001962L/no not_active Application Discontinuation
- 2000-05-15 BG BG104432A patent/BG104432A/bg unknown
- 2000-06-16 NO NO20003107A patent/NO20003107L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
OA11371A (en) | 2004-01-28 |
PL344977A1 (en) | 2001-11-19 |
WO1999020275A1 (fr) | 1999-04-29 |
EP1030665A1 (fr) | 2000-08-30 |
US6376512B1 (en) | 2002-04-23 |
BR9814087A (pt) | 2000-10-03 |
NO20001962L (no) | 2000-06-16 |
CA2306825A1 (fr) | 1999-04-29 |
AU9696198A (en) | 1999-05-10 |
CN1302206A (zh) | 2001-07-04 |
EP1030665A4 (fr) | 2002-11-27 |
NO20003107D0 (no) | 2000-06-16 |
NO20001962D0 (no) | 2000-04-14 |
NO20003107L (no) | 2000-07-26 |
KR20010024533A (ko) | 2001-03-26 |
AP2000001786A0 (en) | 2000-04-16 |
HUP0101022A1 (hu) | 2001-10-28 |
IL135673A0 (en) | 2001-05-20 |
EA200000427A1 (ru) | 2001-02-26 |
JP2001520193A (ja) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG104432A (bg) | Терапевтично използване на хинолинови производни | |
US20030220373A1 (en) | Therapeutic uses of PPAR mediators | |
TW584560B (en) | Pharmaceutical composition of substituted indolealkanoic acids for reducing serum glucose and triglyceride levels and inhibiting angiogenesis | |
KR100709498B1 (ko) | Ppar 수용체 리간드로서의 디아릴 산 유도체 | |
JP2003525217A (ja) | 肥満治療用薬剤 | |
CN101268060A (zh) | 噻唑啉酮和噁唑啉酮类化合物及其作为ptp1b抑制剂的应用 | |
US20210047337A1 (en) | Triazolopyrimidines, their preparation and use | |
TW200803896A (en) | Method of improvement of cognitive function | |
BRPI0615046B1 (pt) | uso de um composto | |
CN101948416A (zh) | 用于治疗代谢紊乱的化合物 | |
EP1572180B1 (fr) | Utilisation d'acides alpha-phenylthiocarboxyliques ayant une activite de reduction du taux du glucose serique et du taux des lipides seriques | |
WO2004093910A1 (fr) | Remede contre des maladies cerebrales neurodegeneratives utilisant un agoniste des ppar$g(d) | |
US10377695B2 (en) | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | |
AU2007257854B2 (en) | Compounds for the treatment of metabolic disorders | |
JP2000500490A (ja) | 糖尿病治療用の4−ヒドロキシクマリン−3−カルボキシアミド | |
TW201818964A (zh) | 使用色胺酸羥化酶抑制劑之方法 | |
WO2021032218A1 (fr) | COMPOSÉ AGONISTE DU RÉCEPTEUR THR-β HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION | |
CN108299411B (zh) | 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途 | |
ZA200506257B (en) | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
JPH09505081A (ja) | 5−リポキシゲナーゼ阻害物質としてのイソキサゾリン化合物 |